Financial Performance - The company achieved operating revenue of CNY 2,074,024,306.24 in 2025, a year-on-year increase of 42.66%[22]. - Total profit reached CNY 291,866,003.92, up 127.39% compared to the previous year[25]. - Net profit attributable to shareholders was CNY 278,788,646.49, reflecting a 110.11% increase year-on-year[25]. - The net profit after deducting non-recurring gains and losses was CNY 270,100,386.55, an increase of 155.86% from the previous year[25]. - The net cash flow from operating activities was CNY 603,664,616.89, a significant increase of 669.04%[25]. - The company's total assets at the end of 2025 were CNY 3,389,475,513.24, representing a 22.99% increase from the beginning of the year[25]. - The net assets attributable to shareholders increased to CNY 2,298,528,233.41, up 12.96% year-on-year[25]. - Basic earnings per share were CNY 2.93, a 109.29% increase compared to the previous year[26]. - The weighted average return on equity was 12.88%, an increase of 6.19 percentage points year-on-year[26]. Dividend Policy - The company plans to distribute a cash dividend of 8.9 RMB per 10 shares, totaling approximately 84.37 million RMB, which represents 30.26% of the net profit attributable to shareholders for the year 2025[4]. - As of December 31, 2025, the company's distributable profits amounted to 500.74 million RMB[4]. - The company will not conduct a capital reserve transfer to increase share capital or issue bonus shares for the year 2025[4]. Audit and Compliance - The company has received a standard unqualified audit report from its accounting firm, indicating the financial report's authenticity and completeness[4]. - The board of directors has confirmed that all members attended the board meeting, ensuring governance compliance[4]. - There are no non-operational fund occupations by controlling shareholders or related parties reported[8]. - The company has not violated decision-making procedures for external guarantees[8]. - The company has no dissenting opinions from the audit committee regarding risk supervision during the reporting period[160]. Research and Development - The company has developed a range of laser products, including pulse fiber lasers and solid-state lasers, with the MOPA pulse fiber laser being the first of its kind to achieve mass production in China[39]. - The company has established an international R&D and sales team centered in Shenzhen and Singapore, serving clients across Asia, North America, and Europe[38]. - The company’s main business focuses on the R&D, production, and sales of laser devices and optical intelligent equipment, targeting precision testing and micro-processing applications[38]. - The total R&D expenditure for the year was approximately ¥175.30 million, representing a 4.60% increase from the previous year's ¥167.58 million[75]. - The company applied for a total of 65 intellectual property rights in 2025, including 14 invention patents and 24 utility model patents, and was granted 62 rights, with 18 being invention patents[72]. Market Expansion and Strategy - The company is expanding its production capacity for MPO fiber optic connectors and fiber array units (FAU) to meet the growing market demand, particularly in data centers and cloud computing[51]. - The company aims to provide personalized solutions while focusing on standardized products in the laser source and core module sectors[38]. - The company is exploring market expansion opportunities and potential mergers and acquisitions to enhance its competitive position in the industry[131]. - The company is focusing on expanding its market presence through innovative product development and strategic investments in R&D, as evidenced by the successful launch of multiple new laser products[78]. Risk Management - The company has outlined various risks and countermeasures in its annual report, emphasizing the importance of risk management[3]. - The company faces risks related to technology upgrades and iterations, which are crucial for maintaining product competitiveness in the rapidly evolving laser industry[84]. - The company has identified potential risks associated with R&D failures, including the inability to meet market demands and the challenges of industrializing new technologies[86]. - The company is actively addressing the risk of talent loss, which is critical for the development of laser technology and products[86]. Corporate Governance - The company maintains strict compliance with corporate governance regulations, ensuring independence from its controlling shareholder in operations and decision-making[136]. - The company emphasizes transparency in information disclosure, ensuring timely and accurate communication with investors[138]. - The company has established a comprehensive salary system that includes fixed salaries, performance bonuses, and stock incentives for management and key technical staff[163]. Employee Engagement and Welfare - The company has implemented an employee stock ownership plan to align employee interests with company performance[140]. - The company has a total of 311 employees holding shares, representing 13.09% of the total employee count[200]. - The company actively engages in public welfare activities, including medical assistance for disadvantaged groups[195]. - The company has established a comprehensive employee rights protection system, including health checks for hazardous positions[199]. Social Responsibility - The company made charitable donations totaling CNY 37.90 million, including contributions to the Shenzhen Charity Association and Hubei Minzu University[193]. - The company donated CNY 229,000 to the Shenzhen Charity Association in June 2025 for a rare disease public welfare project[195]. - The company contributed CNY 20,000 to the Shenzhen Longhua District Charity Association for the 2025 Guangdong "6·30" rural revitalization project[196]. - Total investment in poverty alleviation and rural revitalization projects amounted to CNY 20,000 in December 2025[197].

中原证券股份有限公司 2025 年年度报告 公司代码：601375 公司简称：中原证券 中原证券股份有限公司 2025 年年度报告 1 / 256 中原证券股份有限公司 2025 年年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本公司按照中国企业会计准则编制的 2025 年度财务报告，经信永中和会计师事务所（特殊 普通合伙）审计，为本公司出具了标准无保留意见的审计报告。 四、 公司负责人张秋云女士、主管会计工作负责人郭良勇先生及会计机构负责人韩喜华女士声明： 保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司经本次董事会审议通过的利润分配预案为：每10股派发现金红利人民币0.22元（含税） ，按照截至2025年12月31日公司总股本4,642,884,700股，计算合计拟派发现金红利人民币 102,143,463.40元（含税），公司不进行资本公积金转增股本，不送红股。此预案尚需本公司股 东 ...

无锡农村商业银行股份有限公司2025 年年度报告 公司代码：600908 公司简称：无锡银行 无锡农村商业银行股份有限公司 2025 年年度报告 1 / 212 无锡农村商业银行股份有限公司2025 年年度报告 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 本行拟以实施权益分派股权登记日登记的总股本为基数，每股派发现金股利0.13元（含税）。2025 年中期已按每股0.11元（含税）派发现金股利，2025年全年累计派发每股0.24元现金股利（含税）。 截至报告期末，母公司存在未弥补亏损的相关情况及其对公司分红等事项的影响 □适用 √不适用 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，请投 资者注意投资风险。 重要提示 一、本公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司全体董事出席董事会会议。 三、 信永中和会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、公司负责人陶畅、行长陈红梅、主管会计工 ...

中国能源建设股份有限公司 2025 年年度报告 公司 A 股代码：601868 公司 A 股简称：中国能建 公司 H 股代码：03996 公司 H 股简称：中国能源建设 中国能源建设股份有限公司 2025 年年度报告 1 / 307 中国能源建设股份有限公司 2025 年年度报告 重要提示 一、本公司董事会及董事、高级管理人员保证年度报告内容的真实性、准确性、完整性，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、未出席董事情况 | 未出席董事职务 | 未出席董事姓名 | 未出席董事的原因说明 | 被委托人姓名 | | --- | --- | --- | --- | | 董事 | 刘学诗 | 因其他公务 | 牛向春 | | 董事 | 司欣波 | 因其他公务 | 程念高 | 三、 天健会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、公司负责人倪真、主管会计工作负责人陈勇及会计机构负责人（会计主管人员）刘爱军声明： 保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司于2026年3月27日召开了第三届董 ...

上海新动力汽车科技股份有限公司2025 年年度报告 公司 A 股代码：600841 公司 A 股简称：动力新科 公司 B 股代码：900920 公司 B 股简称：动力 B 股 上海新动力汽车科技股份有限公司 2025 年年度报告 一、本公司董事会及董事、高级管理人员保证年度报告内容的真实性、准确性、完整性，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司全体董事出席董事会会议。 三、德勤华永会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、公司负责人杨怀景、主管会计工作负责人顾耀辉及会计机构负责人（会计主管人员）孙洁声明：保证 年度报告中财务报告的真实、准确、完整。 五、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 根据德勤华永会计师事务所（特殊普通合伙）审计，公司2025年度实现归属于母公司的合并净利润为 287,200.46万元，每股收益2.07元，2025年末合并报表的未分配利润为-244,450.24万元。2025年度母公 司实现的净利润为7,376.46万元，2025年末母公司未分配利润为-192,317.56万元。 因公司2025年 ...

A股股票代码:601211 H股股份代号:02611 国泰海通证券股份有限公司 GUOTAI HAITONG SECURITIES CO., LTD. 2025 年度报告 国泰海通证券股份有限公司 重要提示 年度报告 2025 ANNUAL REPORT 重要提示 一、本公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司全体董事出席董事会会议。 三、毕马威华振会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的 审计报告。 四、公司负责人朱健、主管会计工作负责人张信军及会计机构负责人（会计主管 人员）敖奇顺声明：保证年度报告中财务报告的真实、准确、完整。 五、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司 2025 年度利润分配预案为：以本次分红派息的股权登记日公司总股本扣除公司回购专用证券 账户持有股份后的股本总额为基数，向 A 股股东和 H 股股东每 10 股分配现金红利 3.5 元（含税）。 按照公司截至 2025 年 12 月 31 日的总股数 17,628,925,829 股扣除公司回 ...

Financial Performance - Total revenue for 2025 was CNY 1,696,973,319, a decrease of 16.00% compared to CNY 2,020,143,866 in 2024[22] - Net profit attributable to shareholders was a loss of CNY 128,493,816 in 2025, compared to a loss of CNY 119,985,610 in 2024[22] - The company reported a total loss of CNY 129,059,945 for the year, compared to a loss of CNY 120,404,910 in 2024[22] - Basic earnings per share for 2025 is -0.11 CNY, unchanged from 2024, compared to 0.05 CNY in 2023[24] - Diluted earnings per share for 2025 is also -0.11 CNY, unchanged from 2024, compared to 0.05 CNY in 2023[24] - The weighted average return on equity decreased to -5.05% in 2025 from -4.39% in 2024, a decline of 0.66 percentage points[24] - The gross profit margin decreased by 1.04 percentage points to 0.65%[72] - The net profit attributable to the parent company was -CNY 128 million, a decrease of 7.09% compared to -CNY 120 million in 2024[68] Cash Flow and Dividends - The net cash flow from operating activities was CNY 316,974,833.2 in 2025, a significant recovery from a negative cash flow of CNY -174,359,559 in 2024[22] - The company does not plan to distribute cash dividends or stock dividends for 2025[6] - The cumulative cash dividend amount over the last three fiscal years is CNY 134.51 million, with a cumulative repurchase and cancellation amount of CNY 75.79 million, totaling CNY 210.30 million[152] Assets and Equity - The company's total assets decreased by 9.83% to CNY 3,382,342,092 at the end of 2025 from CNY 3,751,108,759 at the end of 2024[23] - The total equity attributable to shareholders decreased by 4.93% to CNY 2,480,501,713 in 2025 from CNY 2,609,108,377 in 2024[23] Operational Highlights - The company has established a production capacity of 1.8 million cubic meters for engineered wood products across three manufacturing bases in Guangxi and Anhui[37] - The company focuses on differentiated products such as formaldehyde-free boards and high-precision milling boards, catering to diverse applications in furniture manufacturing and construction[37] - The company has implemented a dual-driven development model of "ecology + economy," expanding into high-value-added economic crops since 2019[40] - The company has received multiple certifications, including FSC-FM and CARB/EPA, establishing a green qualification barrier for global market access[38] Market and Industry Trends - The engineered wood industry is positioned as a core area of the wood processing industry, with a focus on sustainable and environmentally friendly material solutions[41] - The total production of engineered wood in China is projected to reach 349.17 million cubic meters by the end of 2024, with a year-on-year growth of 3.9%[43] - The production of particleboard is expected to increase by 12.6% year-on-year, while fiberboard production is anticipated to decline by 5.9%[43] - The company is focusing on domestic market development while expanding into Southeast Asia and the Middle East, leveraging opportunities from the Belt and Road Initiative and RCEP[88] Research and Development - The R&D center has been recognized for its innovation capabilities, with 64 national key research projects undertaken and 84 patents granted, including 19 invention patents[66] - R&D investment is being increased to focus on innovative technologies such as formaldehyde-free and environmentally friendly materials, with a goal to develop a product matrix that emphasizes functionality and scenario application[111] Governance and Compliance - The company is committed to maintaining a robust governance structure, ensuring transparency and compliance with regulatory requirements[118] - The board of directors consists of 7 members, including 3 independent directors, ensuring a balanced governance framework[121] - The company has conducted a special audit on internal control effectiveness, ensuring that the internal control system functions properly to support sustainable development[126] - The company has maintained the independence of its major shareholders and actual controllers, with no reported conflicts of interest or competitive business activities[127] Environmental and Social Responsibility - The company has invested CNY 4.40 million in social responsibility initiatives, focusing on rural revitalization and charitable donations[159] - A total of CNY 11.84 million has been allocated to poverty alleviation and rural revitalization projects during the reporting period[161] - The company is advancing towards green and low-carbon strategies, integrating digital and intelligent technologies into green factory construction[92] Future Outlook - The company aims to leverage its technological advancements in formaldehyde-free products to gain a competitive edge in the upcoming regulatory changes set for 2026[60] - The company plans to enhance its overseas market strategy, focusing on Southeast Asia and the Middle East, leveraging international certifications to penetrate these markets[62] - The company anticipates a significant increase in particleboard production capacity by the end of 2025, which may exacerbate supply-demand imbalances in the industry[112]

青岛海尔生物医疗股份有限公司2025 年年度报告 公司代码：688139 公司简称：海尔生物 青岛海尔生物医疗股份有限公司 2025 年年度报告 1 / 272 青岛海尔生物医疗股份有限公司2025 年年度报告 重要提示 一、本公司董事会及董事、高级管理人员保证年度报告内容的真实性、准确性、完整性，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司上市时未盈利且尚未实现盈利 □是 √否 三、重大风险提示 公司已在本报告中详细阐述公司在经营过程中可能面临的各种风险及应对措施，敬请查阅本 报告第三节"管理层讨论与分析"。 四、公司全体董事出席董事会会议。 五、安永华明会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 如在本报告披露之日起至实施权益分派股权登记日期间，因可转债转股/回购股份/股权激励授 予股份回购注销/重大资产重组股份回购注销等致使公司总股本发生变动的，公司拟维持每股分配 比例不变，相应调整分配总额。 母公司存在未弥补亏损 □适用 √不适用 八、是否存在公司治理特殊安排等重要事项 □适用 √不适用 九、前瞻性陈述的风险声明 √适用 □不适用 六、公司负 ...

NEW CHINA LIFE INSURANCE COMPANY LTD. ழӨ̡δᬗᐧ͋దᬍНՃ ᐧ͋̽Ղ: 601336 ̆˗Ө̡ඟС֗ڎฌвੇቡᄊᐧ͋దᬍНՃ एઑշࣲ 2025 重要提示 重要提示 | 二零二五年年报 01 1 本公司董事会及董事、高级管理人员保证本报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 2 本公司第九届董事会第五次会议于2026年3月27日审议通过了本公司 《2025年年度报告》。会议应出席董事10人，亲自出席董事10人。 3 本公司2025年度财务报告已经德勤华永会计师事务所（特殊普通合 伙）根据中国注册会计师审计准则审计，并出具标准无保留意见的审 计报告。 4 本公司董事长杨玉成先生，总裁、财务负责人龚兴峰先生，总精算师 潘兴先生以及会计机构负责人何章梅女士保证《2025年年度报告》中 财务报告的真实、准确、完整。 5 本公司于2025年中期向全体股东派发现金股利每股0.67元（含税）， 共计20.90亿元 ；本公司拟向全体股东派发2025年末期现金股利每股 2.06元（含税），共计64.26亿元。2025年，本公司拟合 ...

国投中鲁果汁股份有限公司2025 年年度报告 公司代码：600962 公司简称：国投中鲁 国投中鲁果汁股份有限公司 2025 年年度报告 1 / 201 国投中鲁果汁股份有限公司2025 年年度报告 重要提示 一、本公司董事会及董事、高级管理人员保证年度报告内容的真实性、准确性、完整性，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司全体董事出席董事会会议。 三、信永中和会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、公司负责人王炜、主管会计工作负责人刘玉及会计机构负责人（会计主管人员）牛晶晶声明： 保证年度报告中财务报告的真实、准确、完整。 五、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经公司董事会审议通过，2025年度公司拟不进行现金股利分配，亦不实施包括资本公积转增 股本在内的其他形式的利润分配。上述利润分配预案需提交公司2025年年度股东会审议批准。 截至报告期末，母公司存在未弥补亏损的相关情况及其对公司分红等事项的影响 √适用 □不适用 根据信永中和会计师事务所（特殊普通合伙）为公司出具的标准无保留意见审计报告，公司 2025年 ...